OrthoPediatrics (KIDS) Projected to Post Earnings on Thursday

OrthoPediatrics (NASDAQ:KIDS) is expected to issue its Q4 2025 results after the market closes on Thursday, February 26th. Analysts expect OrthoPediatrics to post earnings of ($0.29) per share and revenue of $61.2720 million for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:30 PM ET.

OrthoPediatrics Price Performance

Shares of OrthoPediatrics stock opened at $16.08 on Wednesday. The company has a debt-to-equity ratio of 0.28, a current ratio of 7.40 and a quick ratio of 3.52. OrthoPediatrics has a one year low of $15.28 and a one year high of $26.40. The business’s 50 day simple moving average is $17.60 and its two-hundred day simple moving average is $18.16. The stock has a market capitalization of $403.29 million, a P/E ratio of -8.25 and a beta of 1.12.

Hedge Funds Weigh In On OrthoPediatrics

A number of hedge funds have recently added to or reduced their stakes in KIDS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of OrthoPediatrics by 6.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,995 shares of the company’s stock worth $246,000 after purchasing an additional 645 shares in the last quarter. Russell Investments Group Ltd. boosted its holdings in shares of OrthoPediatrics by 433.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock valued at $26,000 after acquiring an additional 1,139 shares during the last quarter. BNP Paribas Financial Markets raised its holdings in shares of OrthoPediatrics by 60.2% during the third quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock valued at $61,000 after purchasing an additional 1,235 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its holdings in OrthoPediatrics by 5,226.5% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 2,610 shares of the company’s stock worth $46,000 after purchasing an additional 2,561 shares during the last quarter. Finally, Barclays PLC lifted its holdings in shares of OrthoPediatrics by 10.7% during the 4th quarter. Barclays PLC now owns 26,405 shares of the company’s stock valued at $469,000 after buying an additional 2,561 shares during the period. 69.05% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of OrthoPediatrics in a report on Thursday, January 22nd. TD Cowen raised shares of OrthoPediatrics to a “strong-buy” rating in a research note on Tuesday, January 27th. Wall Street Zen cut OrthoPediatrics from a “hold” rating to a “sell” rating in a research note on Saturday. Needham & Company LLC lowered their price target on OrthoPediatrics from $42.00 to $26.00 and set a “buy” rating for the company in a research report on Wednesday, October 29th. Finally, BTIG Research reiterated a “buy” rating and issued a $23.00 price objective on shares of OrthoPediatrics in a research report on Wednesday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $23.89.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.